Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network

Background: There is no standard first line treatment for mantle cell lymphoma. Patients and methods: This was a multicenter phase II pilot study of rituximab and modified hyper-fractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (modified R-hyperCVAD) administered every 28 days fo...

Full description

Saved in:

Bibliographic Details
Published in:	Annals of oncology Vol. 17; no. 9; pp. 1418 - 1423
Main Authors:	Kahl, BS, Longo, WL, Eickhoff, JC, Zehnder, J, Jones, C, Blank, J, McFarland, T, Bottner, W, Rezazedeh, H, Werndli, J, Bailey, HH
Format:	Journal Article
Language:	English
Published:	Oxford Oxford University Press 01-09-2006 Oxford Publishing Limited (England)
Subjects:	Adult Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Murine-Derived Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use biologic therapy Biological and medical sciences chemotherapy Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Dexamethasone - administration & dosage Dexamethasone - adverse effects Dexamethasone - analogs & derivatives Disease-Free Survival Doxorubicin - administration & dosage Doxorubicin - adverse effects Drug Administration Schedule Female Hematologic and hematopoietic diseases Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma, Mantle-Cell - drug therapy Lymphoma, Mantle-Cell - mortality Male mantle cell lymphoma Medical sciences Middle Aged Pharmacology. Drug treatments Pilot Projects Remission Induction Rituximab Survival Analysis Treatment Outcome Vincristine - administration & dosage Vincristine - adverse effects United States North America Wisconsin America biologic therapy Induction Rituximab B cell neoplasm Malignant hemopathy B-Lymphocyte Monoclonal antibody Malignant tumor Non Hodgkin lymphoma Chemotherapy Cancerology Treatment Lymphoproliferative syndrome Immunotherapy Anticytokine Mantle cell lymphoma Network Progression free survival Prolonged
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Background: There is no standard first line treatment for mantle cell lymphoma. Patients and methods: This was a multicenter phase II pilot study of rituximab and modified hyper-fractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (modified R-hyperCVAD) administered every 28 days for four to six cycles followed by rituximab maintenance therapy consisting of four weekly doses every 6 months for 2 years. Unlike traditional hyperCVAD regimens, no methotrexate or cytarabine was administered. Results: Of 22 patients, the overall response rate was 77% and the complete response rate was 64%. With a median follow-up time of 37 months in surviving patients, the median PFS was 37 months and the median OS was not reached. The achievement of a molecular remission did not correlate with improved outcome. The major toxicity was expected myelosuppression. Two patients died during induction treatment. There were no major adverse effects during maintenance therapy. Conclusion: In a multicenter trial, modified R-hyperCVAD was tolerable and effective induction therapy for untreated MCL. Maintenance rituximab appeared to prolong PFS without increasing toxicity.
Bibliography:	istex:4DB0E477E7E3F427873EBF4A6688513640A6E487 ark:/67375/HXZ-ZMBBH5XW-X ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0923-7534 1569-8041
DOI:	10.1093/annonc/mdl127